Drug intelligence / Profile preview

[18F] JNJ-64326067

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[18F] JNJ-64326067 is a novel isoquinoline derivative developed as a positron emission tomography (PET) radiopharmaceutical tracer for the detection and quantitation of tau protein aggregates in the brain, primarily associated with Alzheimer's disease. It acts as a tau aggregate inhibitor with high affinity and selectivity for tau over β-amyloid aggregates, enabling imaging of neurofibrillary tangles characteristic of Alzheimer's pathology. The tracer shows minimal off-target binding including to monoamine oxidases A and B, which can confound imaging results. It was developed by Janssen Global Services LLC and is intended for diagnostic use in nervous system diseases such as Alzheimer's disease through PET imaging to assess tau pathology burden non-invasively.

Other names: [18F]-JNJ-64326067-AAA[18F]-JNJ-067

Targets

Tau aggregates (Microtubule-associated protein tau (pathological form))

Beyond the preview

Go deeper on [18F] JNJ-64326067.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F] JNJ-64326067.

Explore the full profile